Clinical Trial

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Study acronym: TMLI-MA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
Trial Details
NCT Number NCT06598969
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions Myelodysplastic Syndromes, Myeloid Leukemia, Acute
Enrollment 58 participants
Start Date 2024-12-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19